Allogeneic Umbilical Cord Blood Therapy for Stroke | NCT01884155

Studies
Allogeneic Umbilical Cord Blood Therapy for Stroke

NCT01884155

Sponsor

MinYoung Kim, M.D.

Status

Completed

Last Update Posted

Oct 12, 2017Actual

Enrollment

5Actual

Phase

Phase 1

Conditions

Stroke

Interventions

Allogeneic umbilical cord blood therapy

Countries

South Korea

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Oct 2017

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Jun 2013

Primary Completion Date

May 2015Actual

Completion Date

Dec 2015Actual

First Submitted Date

Jun 19, 2013

First Submission Date that Met QC Criteria

Jun 20, 2013

First Posted Date

Jun 21, 2013Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Oct 10, 2017

Last Update Posted Date

Oct 12, 2017Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Not provided

Is FDA Regulated Device

Not provided

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood (UCB) therapy for patients with stroke.

Detailed Description

Stroke is one of the most common etiologies causing disability in developed countries. There remains no proven treatments except tissue plasminogen activator currently. Based on promising results of cell therapy in animal stroke models, efforts to apply cell therapy for patients with stroke has been made. UCB possess various stem or progenitor cells and is known to secrete neurotrophic factors to repair injured brain. This clinical research aims to determine the safety and efficacy of allogeneic UCB for stroke.

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 1

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

5Actual

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Allogeneic umbilical cord blood therapy	Experimental	Allogeneic umbilical cord blood therapy	Procedure: Allogeneic umbilical cord blood therapy

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Allogeneic umbilical cord blood therapy	Procedure		Allogeneic umbilical cord blood therapy

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Changes in Balance		Baseline - 1 month - 3 months - 6 months - 12 months

Secondary Outcomes

Measure	Description	Time Frame
Changes in Mobility		Baseline - 1 month - 3 months - 6 months - 12 months
Changes in Muscle strength and Spasticity		Baseline - 1 month - 3 months - 6 months - 12 months

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Ischemic or hemorrhagic stroke
Onset duration over 12 months
Hemisphere lesions except brain stem and cerebellar lesions
National Institute Health Stroke Scale: 10 to 15

Exclusion Criteria:

Possibility of hypersensitivity drugs used in this study
Uncontrolled hypertension or cardiovascualr diseases
Malignant cancer
Renal or hepatic dysfunction (Consultation to specialist in nephrology or gastroenterology in case of renal or hepatic dysfunction)
Severe pulmonary dysfunction
Traumatic brain injury
Lack of matched UCB

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

Not provided

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Name	Affiliation	Role
MinYoung Kim, M.D., Ph.D.	CHA University	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
CHA Bundang Medical Center, CHA University		Seongnam-si	Gyeonggi-do	463-712	South Korea

Condition Browse Module

MeSH Terms

ID	Term
D020521	Stroke

Ancestor Terms

ID	Term
D002561	Cerebrovascular Disorders
D001927	Brain Diseases
D002493	Central Nervous System Diseases
D009422	Nervous System Diseases

Browse Leaves

Not provided

Browse Branches

Not provided